#For clinicians
Written for prescribing clinicians, with full citation chains.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.
Semaglutide After Pancreatitis: A Case
A new case report describes semaglutide controlling refractory hypertriglyceridemia after six pancreatitis episodes.
WIN-IND: Intas Semaglutide Trial
WIN-IND found similar 24-week HbA1c changes with Intas and reference semaglutide, but its non-inferiority rule needs clarification.
Obesity care outside trials
A new review examines how access, tolerability, persistence, and support can shape anti-obesity treatment outcomes in routine care.
GLP-1 drugs before surgery: what changed
A 2026 surgical review supports risk-based planning for semaglutide and tirzepatide, but it reports no new trial or aspiration rate.
Incretin weight loss in type 1 diabetes
A 70-person study linked liraglutide, semaglutide, or tirzepatide treatment with fat loss, modest lean loss, and stable total-body bone density.
Semaglutide in type 1 diabetes: ADJUST-T1D
ADJUST-T1D found better glucose-and-weight outcomes with semaglutide in selected adults, but it did not test long-term cardiovascular benefit.
GLP-1 drugs in dermatologic disease
A 2026 review links GLP-1 drugs with inflammatory skin disease, but its clearest clinical evidence comes from one psoriatic arthritis trial.
GLP-1 drugs and diabetic foot reports
A 2026 FAERS analysis found a lower proportional reporting signal for diabetic foot complications, but it did not measure patient incidence or prove protection.
MASH fibrosis treatment panel update
An expert panel maps how semaglutide and resmetirom may fit MASH care, while long-term outcomes and direct comparisons remain open.
Finding at-risk MASH without a liver biopsy
With semaglutide approved for MASH, finding the right patients is the bottleneck, and a new study says a liver stiffness scan can do it without a biopsy.
Tirzepatide cuts liver fat despite PNPLA3
A post hoc look at SURPASS-3 MRI finds tirzepatide cut liver fat in type 2 diabetes whether or not patients carried the PNPLA3 I148M gene variant.